Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa
| Autor: | van de Vijver, D A M C, Roos, R A C, Jansen, P A F, Porsius, A J, de Boer, A, Dep Farmaceutische wetenschappen, Sub Pharmacotherapy, Theoretical, LS Ges. van de bouwkunst, Sub Biomol.Mass Spectrometry & Proteom. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Farmacie/Biofarmaceutische wetenschappen (FARM)
Ziekenhuisstructuur en organisatie van de gezondheidszorg Econometric and Statistical Methods: General Epidemiology Geneeskunde (GENK) digestive oral and skin physiology Farmacie(FARM) Bescherming en bevordering van de menselijke gezondheid Public Health Geneeskunde(GENK) Biomedische technologie en medicijnen Internal medicine |
| Zdroj: | British Journal of Clinical Pharmacology, 54(2), 168. NLM (Medline) |
| ISSN: | 0306-5251 |
| Popis: | AIMS: We determined whether the start of selective serotonin reuptake inhibitors (SSRI) in levodopa users was followed by a faster increase of antiparkinsonian drug treatment. METHODS: Selected were all levodopa users of 55 years and older from the PHARMO prescription database. The rate of increase of antiparkinsonian drug treatment was compared using Cox's proportional hazard model for starters of SSRI (n = 15) with starters of tricyclic antidepressants (TCA) (n = 31) and with patients not using antidepressants (n = 304), and was adjusted for age, gender, and duration of levodopa use. RESULTS: The hazard ratio for the SSRI group compared with the TCA group was 4.2 (95% confidence interval 1.4, 12.6) and compared with the second control group was 2.7 (1.2, 5.2). CONCLUSIONS: The start of SSRI therapy in levodopa users is followed by a faster increase of antiparkinsonian drug treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text